Fiasp FlexTouch is a faster-acting mealtime insulin aspart from Novo Nordisk, supplied in a 3 ml disposable pre-filled pen containing 300 units. It is the same insulin aspart molecule found in conventional rapid-acting insulin, but reformulated with nicotinamide (vitamin B3) and L-arginine so that absorption from the injection site begins sooner. This earlier onset more closely matches the natural insulin rise that follows eating, which helps blunt the post-meal glucose spike in adults and children with type 1 or type 2 diabetes mellitus. The FlexTouch pen has a spring-loaded, push-button mechanism that needs no extra force at higher doses, making dialling and delivering an accurate dose straightforward.

Key Features

• Faster-acting insulin aspart – absorption begins earlier than conventional mealtime insulin.
• Can be taken at the start of a meal, or within 20 minutes of starting to eat.
• Disposable FlexTouch pen holding 300 units in 3 ml (100 U/ml), dialled in 1-unit steps.
• Push-button release needs no extra force at large doses.
• Clear, colourless solution – no resuspension or mixing required before injecting.
• Manufactured by Novo Nordisk A/S, Denmark.

Composition

• One pre-filled pen contains 300 units of insulin aspart in 3 ml solution
• 1 ml contains 100 units of insulin aspart (equivalent to 3.5 mg)
• Nicotinamide (vitamin B3) 20.76 mg and arginine as L-arginine HCl 3.48 mg
• Phenol 1.50 mg and metacresol 1.72 mg as preservatives
• Glycerol, zinc acetate, disodium phosphate dihydrate and water for injections q.s.

Uses

• Mealtime (bolus) blood glucose control in type 1 diabetes mellitus.
• Mealtime blood glucose control in type 2 diabetes mellitus alongside basal insulin or oral medicines.
• Basal-bolus regimens where a rapid post-meal response is needed.

How to Use

• Use only as prescribed. Your doctor sets the dose based on your blood glucose readings and meals.
• Check that the solution is clear and colourless before every injection. Do not use it if it looks cloudy or has particles.
• Attach a new NovoTwist, NovoFine or NovoFine Plus needle (up to 8 mm) for each dose. Needles are not supplied with the pen.
• Inject subcutaneously into the abdomen, upper arm or thigh, rotating the site each time.
• Take the dose at the start of the meal, or within 20 minutes of starting to eat.
• Discard the needle after each injection and keep the cap on the pen. A pen is for single-patient use only.

Precautions

• Schedule H and Schedule G prescription drug. Not to be sold by retail without the prescription of a Registered Medical Practitioner. It is dangerous to take this preparation except under medical supervision.
• Because it acts sooner than older mealtime insulins, hypoglycaemia can occur earlier after the injection – always keep a fast source of sugar to hand.
• Do not inject if a meal is delayed or skipped without checking with your doctor.
• Kidney or liver disease, illness, alcohol and changes in exercise can all alter your insulin requirement.
• Never switch insulin brand, type or strength without medical advice.
• Take care when driving or using machinery if your glucose control is unstable.

Side Effects

• Hypoglycaemia (low blood sugar) – the most common effect
• Injection site reactions such as redness, swelling or itching
• Lipodystrophy if injection sites are not rotated
• Weight gain
• Rash, itching or allergic reactions

Storage

• Before opening: store in a refrigerator between 2°C and 8°C. Do not freeze.
• During use: keep refrigerated (2°C–8°C) or below 30°C, and use within 4 weeks.
• Keep the cap on the pen to protect it from light, and keep out of the sight and reach of children.

Legal Disclaimer: Fiasp FlexTouch is a prescription-only medicine. This information is for educational purposes and does not replace the advice of a qualified doctor or pharmacist. Always follow the dose and regimen prescribed for you, and consult your physician before making any change to your insulin therapy.

The post Fiasp FlexTouch 100 IU/ml Pre-filled Pen appeared first on PMC Herbals.

Ranibizumab 2.3 mg Injection u2013 Anti-VEGF Treatment for Retinal Eye Disorders

Ranibizumab 2.3 mg Injection contains Ranibizumab 2.3 mg in 0.23 ml, equivalent to a concentration of 10 mg/ml. It is a prescription ophthalmic medicine supplied in a single-use vial for administration directly into the eye. Ranibizumab is an anti-VEGF medicine that blocks vascular endothelial growth factor A. This protein contributes to the growth and leakage of abnormal blood vessels in the retina, which may cause retinal swelling, bleeding, and loss of vision. Ranibizumab Injection must be administered only by a qualified ophthalmologist experienced in intravitreal injections. The treatment dose, injection frequency, and duration depend on the diagnosed retinal condition, eye examinations, retinal imaging results, and response to treatment.

Key Features

• Contains Ranibizumab: An anti-VEGF monoclonal antibody fragment.
• Supports Retinal Treatment: Helps control abnormal blood-vessel growth and fluid leakage within the retina.
• Single-Use Vial: Contains 2.3 mg of ranibizumab in 0.23 ml solution.
• Intravitreal Administration: Injected directly into the vitreous cavity of the eye.
• Specialist-Only Treatment: Must be administered by a trained ophthalmologist.
• Cold-Chain Medicine: Requires refrigerated storage and protection from light.

Active Ingredient

• Ranibizumab 2.3 mg/0.23 ml: An anti-VEGF medicine that helps reduce abnormal retinal blood-vessel growth and vascular leakage.

Uses

• Neovascular or wet age-related macular degeneration.
• Diabetic macular edema.
• Macular edema following retinal vein occlusion.
• Diabetic retinopathy in eligible patients.
• Visual impairment caused by choroidal neovascularization.
• Other retinal conditions can be specifically diagnosed and treated by an ophthalmologist.

How It Is Administered

• Ranibizumab must be administered only by a qualified ophthalmologist.
• It is given as an intravitreal injection directly into the affected eye.
• It must not be self-administered or injected into a vein, muscle, or under the skin.
• The ophthalmologist will determine the exact dose required for each injection.
• The 2.3 mg stated on the vial represents the total vial content and not necessarily the amount administered.
• The vial is intended for single use only, and any unused solution must be discarded.
• Strict sterile and aseptic techniques must be followed during preparation and administration.

Warning

• Serious Eye Infection: Intravitreal injections may cause endophthalmitis, a potentially sight-threatening infection inside the eye.
• Retinal Complications: Retinal tear, retinal detachment, intraocular inflammation, bleeding, or traumatic cataract may occur.
• Increased Eye Pressure: Intraocular pressure may increase temporarily after the injection.

Possible Side Effects

• Eye pain, irritation, itching, or discomfort.
• Eye redness or bleeding on the surface of the eye.
• Temporary blurred vision or visual disturbances.
• Floaters or a foreign-body sensation in the eye.
• Dry eye or increased tearing.
• Increased pressure inside the eye.
• Headache.
• Allergic reactions such as rash, itching, or swelling.

Storage

• Store in a refrigerator between 2u00b0C and 8u00b0C.
• Do not freeze.
• Keep the vial in its original carton to protect it from light.
• Do not shake the vial.
• Do not use if the solution appears cloudy, discoloured, or contains visible particles.
• Do not use if the vial or packaging is opened, damaged, or tampered with.
• The vial is intended for single use only.
• Keep out of reach of children and unauthorized individuals.

Legal Disclaimer: Ranibizumab 2.3 mg Injection is a prescription ophthalmic biological medicine intended exclusively for intravitreal administration by a qualified ophthalmologist. It may cause serious eye-related or systemic adverse reactions. This information is provided for educational purposes only and should not replace professional medical advice, diagnosis, treatment, or the official instructions supplied with the medicine.

The post Ranibizumab 2.3 mg Injection appeared first on PMC Herbals.